(S)-nicotine multiple interactions ISO RGD:1316614 6480464 [Nicotine co-treated with 1-Methyl-4-phenyl-1 more ... CTD PMID:20230807 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine multiple interactions ISO RGD:1316614 6480464 [Caffeine co-treated with 1-Methyl-4-phenyl-1 more ... CTD PMID:20230807 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine decreases expression ISO RGD:1316614 6480464 1-Methyl-4-phenyl-1 more ... CTD PMID:20230807 17alpha-ethynylestradiol affects expression ISO RGD:1316614 6480464 Ethinyl Estradiol affects the expression of IRX3 mRNA CTD PMID:17555576 17alpha-ethynylestradiol multiple interactions ISO RGD:1316614 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in decreased expression of IRX3 mRNA CTD PMID:17942748 17alpha-ethynylestradiol decreases expression ISO RGD:1316614 6480464 Ethinyl Estradiol results in decreased expression of IRX3 mRNA CTD PMID:17942748 17beta-estradiol decreases expression ISO RGD:1316613 6480464 Estradiol results in decreased expression of IRX3 mRNA CTD PMID:21185374 17beta-estradiol increases expression ISO RGD:1316614 6480464 Estradiol results in increased expression of IRX3 mRNA CTD PMID:19484750 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1316614 6480464 Tetrachlorodibenzodioxin affects the expression of IRX3 mRNA CTD PMID:24058054 , PMID:28922406 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1316613 6480464 Tetrachlorodibenzodioxin results in decreased expression of IRX3 mRNA CTD PMID:20106945 more ... 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1316614 6480464 Tetrachlorodibenzodioxin results in increased expression of IRX3 mRNA CTD PMID:17586704 , PMID:19770486 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1316614 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in decreased expression of IRX3 mRNA CTD PMID:17942748 4-hydroxyphenyl retinamide decreases expression ISO RGD:1316614 6480464 Fenretinide results in decreased expression of IRX3 mRNA CTD PMID:28973697 5-aza-2'-deoxycytidine affects expression ISO RGD:1316613 6480464 Decitabine affects the expression of IRX3 mRNA CTD PMID:23300844 aflatoxin B1 increases expression ISO RGD:1316614 6480464 Aflatoxin B1 results in increased expression of IRX3 mRNA CTD PMID:19770486 aflatoxin B1 increases methylation ISO RGD:1316613 6480464 Aflatoxin B1 results in increased methylation of IRX3 gene CTD PMID:28458013 all-trans-retinoic acid increases expression ISO RGD:1316614 6480464 Tretinoin results in increased expression of IRX3 mRNA CTD PMID:16604517 all-trans-retinoic acid affects expression ISO RGD:1316613 6480464 Tretinoin affects the expression of IRX3 mRNA CTD PMID:31600526 all-trans-retinoic acid increases expression ISO RGD:1316613 6480464 Tretinoin results in increased expression of IRX3 mRNA CTD PMID:21934132 all-trans-retinoic acid decreases expression ISO RGD:1316613 6480464 Tretinoin results in decreased expression of IRX3 mRNA CTD PMID:17218384 , PMID:33167477 atrazine affects methylation EXP 6480464 Atrazine affects the methylation of IRX3 gene CTD PMID:28931070 avobenzone decreases expression ISO RGD:1316613 6480464 avobenzone results in decreased expression of IRX3 mRNA CTD PMID:31016361 azathioprine decreases expression ISO RGD:1316613 6480464 Azathioprine results in decreased expression of IRX3 mRNA CTD PMID:22623647 benzo[a]pyrene decreases expression ISO RGD:1316614 6480464 Benzo(a)pyrene results in decreased expression of IRX3 mRNA CTD PMID:22228805 benzo[a]pyrene decreases expression ISO RGD:1316613 6480464 Benzo(a)pyrene results in decreased expression of IRX3 mRNA CTD PMID:26238291 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of IRX3 mRNA CTD PMID:25181051 bisphenol A affects methylation ISO RGD:1316614 6480464 bisphenol A affects the methylation of IRX3 promoter CTD PMID:27334623 butan-1-ol multiple interactions ISO RGD:1316613 6480464 [[Gasoline co-treated with 1-Butanol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of IRX3 mRNA CTD PMID:29432896 C60 fullerene increases expression EXP 6480464 fullerene C60 results in increased expression of IRX3 mRNA CTD PMID:19167457 cadmium dichloride increases methylation EXP 6480464 Cadmium Chloride results in increased methylation of IRX3 promoter CTD PMID:22457795 caffeine multiple interactions ISO RGD:1316614 6480464 [Caffeine co-treated with 1-Methyl-4-phenyl-1 more ... CTD PMID:20230807 calcitriol decreases expression ISO RGD:1316613 6480464 Calcitriol results in decreased expression of IRX3 mRNA CTD PMID:16002434 carbamazepine affects expression ISO RGD:1316613 6480464 Carbamazepine affects the expression of IRX3 mRNA CTD PMID:25979313 carbon nanotube decreases expression ISO RGD:1316614 6480464 Nanotubes more ... CTD PMID:25554681 cisplatin affects expression ISO RGD:1316613 6480464 Cisplatin affects the expression of IRX3 mRNA CTD PMID:23300844 cisplatin multiple interactions ISO RGD:1316613 6480464 [Cisplatin co-treated with jinfukang] results in decreased expression of IRX3 mRNA CTD PMID:27392435 copper(II) sulfate decreases expression ISO RGD:1316613 6480464 Copper Sulfate results in decreased expression of IRX3 mRNA CTD PMID:19549813 cyclosporin A increases expression ISO RGD:1316614 6480464 Cyclosporine results in increased expression of IRX3 mRNA CTD PMID:19770486 cyclosporin A decreases expression ISO RGD:1316613 6480464 Cyclosporine results in decreased expression of IRX3 mRNA CTD PMID:20106945 , PMID:25562108 decabromodiphenyl ether increases expression EXP 6480464 decabromobiphenyl ether results in increased expression of IRX3 mRNA CTD PMID:23914054 dioxygen multiple interactions ISO RGD:1316614 6480464 [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of IRX3 mRNA CTD PMID:30529165 dorsomorphin multiple interactions ISO RGD:1316613 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 doxorubicin decreases expression ISO RGD:1316613 6480464 Doxorubicin results in decreased expression of IRX3 mRNA CTD PMID:29803840 entinostat increases expression ISO RGD:1316613 6480464 entinostat results in increased expression of IRX3 mRNA CTD PMID:26272509 entinostat multiple interactions ISO RGD:1316613 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX3 mRNA CTD PMID:27188386 formaldehyde decreases expression ISO RGD:1316613 6480464 Formaldehyde results in decreased expression of IRX3 mRNA CTD PMID:20655997 furan decreases expression EXP 6480464 furan results in decreased expression of IRX3 mRNA CTD PMID:27387713 hydralazine multiple interactions ISO RGD:1316613 6480464 [Hydralazine co-treated with Valproic Acid] results in increased expression of IRX3 mRNA CTD PMID:17183730 methylmercury chloride increases expression ISO RGD:1316613 6480464 methylmercuric chloride results in increased expression of IRX3 mRNA CTD PMID:26272509 methylmercury chloride multiple interactions ISO RGD:1316613 6480464 [NOG protein co-treated with methylmercuric chloride co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX3 mRNA CTD PMID:27188386 mono(2-ethylhexyl) phthalate affects expression ISO RGD:1316614 6480464 mono-(2-ethylhexyl)phthalate affects the expression of IRX3 mRNA CTD PMID:21195148 Monobutylphthalate affects expression ISO RGD:1316614 6480464 monobutyl phthalate affects the expression of IRX3 mRNA CTD PMID:21195148 Monobutylphthalate increases expression EXP 6480464 monobutyl phthalate results in increased expression of IRX3 mRNA CTD PMID:29162477 N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal decreases expression ISO RGD:1316614 6480464 benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of IRX3 mRNA CTD PMID:25566086 N-nitrosodiethylamine increases expression ISO RGD:1316614 6480464 Diethylnitrosamine results in increased expression of IRX3 mRNA CTD PMID:24535843 nicotine multiple interactions ISO RGD:1316614 6480464 [Nicotine co-treated with 1-Methyl-4-phenyl-1 more ... CTD PMID:20230807 nitrofen increases expression EXP 6480464 nitrofen results in increased expression of IRX3 mRNA, nitrofen results in increased expression of IRX3 protein CTD PMID:21238641 oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of IRX3 mRNA, [Topotecan co-treated with oxaliplatin] results in increased expression of IRX3 mRNA CTD PMID:25729387 oxaliplatin increases expression EXP 6480464 oxaliplatin results in increased expression of IRX3 mRNA CTD PMID:25729387 panobinostat multiple interactions ISO RGD:1316613 6480464 [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX3 mRNA CTD PMID:27188386 panobinostat increases expression ISO RGD:1316613 6480464 panobinostat results in increased expression of IRX3 mRNA CTD PMID:26272509 pirinixic acid multiple interactions ISO RGD:1316614 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of IRX3 mRNA CTD PMID:19710929 quercetin decreases expression ISO RGD:1316613 6480464 Quercetin results in decreased expression of IRX3 mRNA CTD PMID:21632981 resveratrol multiple interactions ISO RGD:1316613 6480464 [Plant Extracts co-treated with Resveratrol] results in decreased expression of IRX3 mRNA CTD PMID:23557933 rotenone decreases expression ISO RGD:1316613 6480464 Rotenone results in decreased expression of IRX3 mRNA CTD PMID:29955902 SB 431542 multiple interactions ISO RGD:1316613 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 silicon dioxide increases expression ISO RGD:1316613 6480464 Silicon Dioxide analog results in increased expression of IRX3 mRNA CTD PMID:23806026 silver atom decreases expression ISO RGD:1316613 6480464 Silver results in decreased expression of IRX3 mRNA CTD PMID:26014281 silver(0) decreases expression ISO RGD:1316613 6480464 Silver results in decreased expression of IRX3 mRNA CTD PMID:26014281 sodium dodecyl sulfate decreases expression ISO RGD:1316613 6480464 Sodium Dodecyl Sulfate results in decreased expression of IRX3 mRNA CTD PMID:31734321 tamoxifen affects expression ISO RGD:1316614 6480464 Tamoxifen affects the expression of IRX3 mRNA CTD PMID:17555576 temozolomide decreases expression ISO RGD:1316613 6480464 Temozolomide results in decreased expression of IRX3 mRNA CTD PMID:31758290 testosterone increases expression ISO RGD:1316614 6480464 Testosterone deficiency results in increased expression of IRX3 mRNA CTD PMID:33848595 testosterone increases expression ISO RGD:1316613 6480464 Testosterone results in increased expression of IRX3 mRNA CTD PMID:33359661 thapsigargin decreases expression ISO RGD:1316613 6480464 Thapsigargin results in decreased expression of IRX3 mRNA CTD PMID:29453283 thioacetamide increases expression EXP 6480464 Thioacetamide results in increased expression of IRX3 mRNA CTD PMID:34492290 topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of IRX3 mRNA, [Topotecan co-treated with oxaliplatin] results in increased expression of IRX3 mRNA CTD PMID:25729387 topotecan increases expression EXP 6480464 Topotecan results in increased expression of IRX3 mRNA CTD PMID:25729387 trichostatin A increases expression ISO RGD:1316613 6480464 trichostatin A results in increased expression of IRX3 mRNA CTD PMID:24935251 , PMID:26272509 trichostatin A multiple interactions ISO RGD:1316613 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX3 mRNA CTD PMID:27188386 triclosan decreases expression ISO RGD:1316613 6480464 Triclosan results in decreased expression of IRX3 mRNA CTD PMID:30510588 troglitazone decreases expression ISO RGD:1316614 6480464 troglitazone results in decreased expression of IRX3 mRNA CTD PMID:12732648 urethane decreases expression ISO RGD:1316613 6480464 Urethane results in decreased expression of IRX3 mRNA CTD PMID:28818685 valproic acid multiple interactions ISO RGD:1316613 6480464 [Hydralazine co-treated with Valproic Acid] results in increased expression of IRX3 mRNA more ... CTD PMID:17183730 , PMID:27188386 valproic acid decreases expression ISO RGD:1316613 6480464 Valproic Acid results in decreased expression of IRX3 mRNA CTD PMID:23179753 , PMID:27188386 valproic acid increases expression ISO RGD:1316613 6480464 Valproic Acid results in increased expression of IRX3 mRNA CTD PMID:23179753 more ... valproic acid increases methylation ISO RGD:1316613 6480464 Valproic Acid results in increased methylation of IRX3 gene CTD PMID:29154799 valproic acid affects expression ISO RGD:1316613 6480464 Valproic Acid affects the expression of IRX3 mRNA CTD PMID:25979313 vinclozolin affects expression EXP 6480464 vinclozolin affects the expression of IRX3 mRNA CTD PMID:19015723 zoledronic acid decreases expression ISO RGD:1316613 6480464 zoledronic acid results in decreased expression of IRX3 mRNA CTD PMID:24714768